Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Febrile Neutropenia 2Polycystic Ovary Syndrome 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Inflammation 1Hematologic Neoplasms 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Burkitt Lymphoma 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Paclitaxel 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Bortezomib 2vandetanib 1umbralisib 1ublituximab 1regorafenib 1pomalidomide 1pembrolizumab 1nilotinib 1marizomib 1lutetium Lu 177 dotatate 1grapiprant 1fludarabine phosphate 1fludarabine 1durvalumab 1cemiplimab 1carotuximab 1axicabtagene ciloleucel 1avelumab 1Thioctic Acid 1Tamoxifen 1Receptors, Interleukin-6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡